Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H13NO4 |
| Molecular Weight | 211.2149 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COc1cc(ccc1O)C[C@@]([H])(C(=O)O)N
InChI
InChIKey=PFDUUKDQEHURQC-ZETCQYMHSA-N
InChI=1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)/t7-/m0/s1
| Molecular Formula | C10H13NO4 |
| Molecular Weight | 211.2149 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans. | 1967 Feb |
|
| 3-O-methyldopa, a new precursor of dopamine. | 1971 Apr 23 |
|
| Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. | 2006 Jan |
Sample Use Guides
mice: 200 or 400 mg/kg (ip)
rats: 3, 10 or 30 mg/kg (ip)
rats: 1 uM (icv)
Route of Administration:
Other
The number of tyrosine hydroxylase-positive dopaminergic neurons was not affected by L-DOPA treatment in mesencephalic neurons alone. However, the increase in viability of dopaminergic neurons in the presence of astrocytes was further enhanced after methyl-L-DOPA treatment (25 µM) in mixed cultured mesencephalic neurons and striatal astrocytes. The neuroprotective effect of 25 µM L-DOPA was almost completely inhibited by simultaneous treatment with 3-O-methyl-DOPA (10 or 100 µM).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 05:59:14 UTC 2021
by
admin
on
Sat Jun 26 05:59:14 UTC 2021
|
| Record UNII |
V3O7J20DWN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
V3O7J20DWN
Created by
admin on Sat Jun 26 05:59:15 UTC 2021 , Edited by admin on Sat Jun 26 05:59:15 UTC 2021
|
PRIMARY | |||
|
9307
Created by
admin on Sat Jun 26 05:59:15 UTC 2021 , Edited by admin on Sat Jun 26 05:59:15 UTC 2021
|
PRIMARY | |||
|
3-O-Methyldopa
Created by
admin on Sat Jun 26 05:59:15 UTC 2021 , Edited by admin on Sat Jun 26 05:59:15 UTC 2021
|
PRIMARY | |||
|
300-48-1
Created by
admin on Sat Jun 26 05:59:15 UTC 2021 , Edited by admin on Sat Jun 26 05:59:15 UTC 2021
|
PRIMARY | |||
|
C008404
Created by
admin on Sat Jun 26 05:59:15 UTC 2021 , Edited by admin on Sat Jun 26 05:59:15 UTC 2021
|
PRIMARY | |||
|
M7398
Created by
admin on Sat Jun 26 05:59:15 UTC 2021 , Edited by admin on Sat Jun 26 05:59:15 UTC 2021
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
RACEMATE -> ENANTIOMER |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
When decarboxylation of levodopa is prevented by carbidopa, COMT becomes the major metabolizing enzyme for levodopa, catalyzing its metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD).
|
